Andy Schwab - Profile and Investment Details

Investor Profile

Andy Schwab is a Venture Capital, Founder, Private Equity Firm, Investor based in San Francisco, California, United States with a diverse investment portfolio that includes companies such as Precision NanoSystem, Vor Biopharma, Aprea, Arvinas, GenePeeks, Miikana Therapeutics, RareCyte, Portal Instruments, Entrada Therapeutics, Ceterix Orthopaedics, Audentes Therapeutics, CinCor Pharma, Homology Medicines, Cabaletta Bio, Flexion Therapeutics, Expansion Therapeutics, Spyryx Biosciences, Ensoma, Cleave Therapeutics, Nohla Therapeutics, scPharmaceuticals, Wildcat Discovery Technologies, Scientist.com, Relypsa, Purigen Biosystems, Epirus Biopharmaceuticals, CAMP4 Therapeutics, RallybioPulmatrix, Crinetics Pharmaceuticals, NodThera, Kinaset Therapeutics, CymaBay Therapeutics, Calibrium, Inipharm, Kinestral Technologies, Magnetic Insight, TMRW Life Sciences, Pearl Therapeutics, National Venture Capital Association, Chrono Therapeutics, Impel NeuroPharma, Igenica, Nouscom, Davidson College, Novira Therapeutics, Bird Rock Bio, Viveve, Enliven Therapeutics, Millendo Therapeutics, Pear Therapeutics, Achaogen, Escient Pharmaceuticals, Artiva Biotherapeutics, California Academy of Sciences, Cidara Therapeutics, Anaphore, Akouos, Bellerophon Therapeutics, IDEAYA Biosciences, BlueLight Therapeutics, DVS Sciences, Neurogastrx, Novome Biotechnologies, . Over time, Andy Schwab has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Andy Schwab is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Genetics, Life Science, Software, Biotechnology, Genomics, Digital Health, Medical, Therapeutics, Media and Entertainment, Emergency Medicine, Pharmaceuticals may find it worthwhile to explore potential connections with Andy Schwab, as their portfolio suggests a familiarity and interest in this area.

Understanding Andy Schwab’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.